CPAL
Central **P**ennsylvania **A**lliance **L**aboratory

Technical Bulletin

No. 64

May 31, 2007

HIV Screening Assay Change

Contact:
Dr. Jeffrey Wisotzkey, 717-851-1422
Technical Director, CPAL

Effective Date: June 4, 2007

Summary: Effective June 4, 2007 CPAL will convert to the Bio-Rad / Genetics Systems™ HIV-1/HIV-2 Plus O EIA test for blood donor screening and patient testing. This assay replaces the Bio-Rad / Genetics Systems™ HIV-1/HIV-2 Peptide EIA test.

This assay is the Genetic Systems Corporation enzyme immunoassay utilizing recombinant proteins and synthetic peptides for the detection of antibodies to HIV-1 (Groups M and O) and/or HIV-2 in human serum, plasma, and cadaveric serum specimens. It is indicated as a screening test for serum, plasma, and cadaveric serum specimens and as an aid in the diagnosis of infections with HIV-1 and /or HIV-2.

The Genetic Systems HIV-1/HIV-2 Plus O EIA assay is based on the principle of the direct antibody sandwich technique. The purified antigens used in this assay are: gp160 and p24 recombinant proteins derived from HIV-1; a peptide representing the immunodominant region of the HIV-2 transmembrane glycoprotein, gp36; and a synthetic polypeptide mimicking an artificial HIV-1 group O specific epitope.

Validation and pre-implementation procedures have been completed in May 2007 at CPAL.